The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Efficacy and tolerability results from a Phase I/II study of LOXO-305 in B-cell malignancies
Anthony Mato, MD, Memorial Sloan Kettering Cancer Center, New York, NY presents the results of the BRUIN Phase I/II trial (NCT 03740529) of LOXO-305 in patients with B-cell malignancies. LOXO-305 is a highly selective, non-covalent BTK inhibitor that targets both wildtype and C481-mutated BTK, overcoming substantial limitations of current covalent BTKis. 186 previously treated patients were enrolled, with B-cell malignancies including chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and diffuse large B-cell lymphoma. 7 dose levels were used in the dose-escalation study, but there were no dose reductions or dose-limiting toxicities. Results show a high overall response rate, deepening over time in those with ≥6 months follow up. LOXO-305 was very well tolerated, showed promising activity, and a recommended Phase II dose of 200mg QD was established. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
